The S&P 500 has been buoyant mainly because of A.I. fever, while bonds are having another mediocre year. But as an investor, our columnist is staying the course.
OpenAI and the FDA are reportedly discussing AI for drug evaluations
- today, 5:09 PM
- techcrunch.com
- 0
No comments